Literature DB >> 32725400

Involvement of adenosine A1 and A2A receptors on guanosine-mediated anti-tremor effects in reserpinized mice.

C M Massari1,2, L C Constantino2,3, N F Marques1,2, L B Binder2,3, M Valle-León4,5, M López-Cano4,5, V Fernández-Dueñas4,5, F Ciruela4,5, C I Tasca6,7,8.   

Abstract

Parkinson's disease (PD) signs and symptoms regularly include tremor. Interestingly, the nucleoside guanosine (GUO) has already proven to be effective in reducing reserpine-induced tremulous jaw movements (TJMs) in rodent models, thus becoming a promising antiparkinsonian drug. Here, we aimed at revealing the mechanism behind GUO antiparkinsonian efficacy by assessing the role of adenosine A1 and A2A receptors (A1R and A2AR) on GUO-mediated anti-tremor effects in the reserpinized mouse model of PD. Reserpinized mice showed elevated reactive oxygen species (ROS) production and cellular membrane damage in striatal slices assessed ex vivo and GUO treatment reversed ROS production. Interestingly, while the simultaneous administration of sub-effective doses of GUO (5 mg/kg) and SCH58261 (0.01 mg/kg), an A2AR antagonist, precluded reserpine-induced TJMs, these were ineffective on reverting ROS production in ex vivo experiments. Importantly, GUO was able to reduce TJM and ROS production in reserpinized mouse lacking the A2AR, thus suggesting an A2AR-independent mechanism of GUO-mediated effects. Conversely, the administration of DPCPX (0.75 mg/kg), an A1R antagonist, completely abolished both GUO-mediated anti-tremor effects and blockade of ROS production. Overall, these results indicated that GUO anti-tremor and antioxidant effects in reserpinized mice were A1R dependent but A2AR independent, thus suggesting a differential participation of adenosine receptors in GUO-mediated effects.

Entities:  

Keywords:  Adenosine receptors; Guanosine; Reserpine; Tremor

Year:  2020        PMID: 32725400      PMCID: PMC7524909          DOI: 10.1007/s11302-020-09716-z

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  57 in total

1.  Special Report: The 1996 Guide for the Care and Use of Laboratory Animals.

Authors:  J. Derrell Clark; Gerald F. Gebhart; Janet C. Gonder; Michale E. Keeling; Dennis F. Kohn
Journal:  ILAR J       Date:  1997

2.  Differential effect of acute reserpine administration on D-1 and D-2 dopaminergic receptor density and function in rat striatum.

Authors:  P Liberini; E Nisoli; C Missale; M Memo; M Buonamici; A Rossi; P F Spano
Journal:  Neurochem Int       Date:  1989       Impact factor: 3.921

3.  Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas.

Authors:  P Svenningsson; C Le Moine; B Kull; R Sunahara; B Bloch; B B Fredholm
Journal:  Neuroscience       Date:  1997-10       Impact factor: 3.590

4.  Guanosine Protects Striatal Slices Against 6-OHDA-Induced Oxidative Damage, Mitochondrial Dysfunction, and ATP Depletion.

Authors:  Naiani Ferreira Marques; Caio Marcos Massari; Carla Inês Tasca
Journal:  Neurotox Res       Date:  2018-11-12       Impact factor: 3.911

5.  Effect of orally administered guanosine on seizures and death induced by glutamatergic agents.

Authors:  D R Lara; A P Schmidt; M E Frizzo; J S Burgos; G Ramírez; D O Souza
Journal:  Brain Res       Date:  2001-09-07       Impact factor: 3.252

6.  Adenosine A1 receptor blockade selectively potentiates the motor effects induced by dopamine D1 receptor stimulation in rodents.

Authors:  P Popoli; L Giménez-Llort; A Pezzola; R Reggio; E Martínez; K Fuxe; S Ferré
Journal:  Neurosci Lett       Date:  1996-11-08       Impact factor: 3.046

7.  Guanosine protects glial cells against 6-hydroxydopamine toxicity.

Authors:  Patricia Giuliani; Patrizia Ballerini; Silvana Buccella; Renata Ciccarelli; Michel P Rathbone; Silvia Romano; Iolanda D'Alimonte; Francesco Caciagli; Patrizia Di Iorio; Mieczyslaw Pokorski
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Guanosine Anxiolytic-Like Effect Involves Adenosinergic and Glutamatergic Neurotransmitter Systems.

Authors:  Roberto Farina Almeida; Daniel Diniz Comasseto; Denise Barbosa Ramos; Gisele Hansel; Eduardo R Zimmer; Samanta Oliveira Loureiro; Marcelo Ganzella; Diogo Onofre Souza
Journal:  Mol Neurobiol       Date:  2016-01-07       Impact factor: 5.590

9.  Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.

Authors:  John D Salamone; Lyndsey E Collins-Praino; Marta Pardo; Samantha J Podurgiel; Younis Baqi; Christa E Müller; Michael A Schwarzschild; Mercè Correa
Journal:  Eur Neuropsychopharmacol       Date:  2012-09-01       Impact factor: 4.600

Review 10.  Functional and Neuroprotective Role of Striatal Adenosine A2A Receptor Heterotetramers.

Authors:  Sergi Ferré; Francisco Ciruela
Journal:  J Caffeine Adenosine Res       Date:  2019-09-17
View more
  4 in total

Review 1.  Neuroprotective Effects of Guanosine in Ischemic Stroke-Small Steps towards Effective Therapy.

Authors:  Karol Chojnowski; Mikolaj Opielka; Wojciech Nazar; Przemyslaw Kowianski; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-27       Impact factor: 5.923

2.  The antidepressant-like effect of guanosine involves the modulation of adenosine A1 and A2A receptors.

Authors:  Anderson Camargo; Luis E B Bettio; Priscila B Rosa; Julia M Rosa; Glorister A Altê; Ana Lúcia S Rodrigues
Journal:  Purinergic Signal       Date:  2022-09-27       Impact factor: 3.950

3.  Adenosine A1 and A2A receptors are involved on guanosine protective effects against oxidative burst and mitochondrial dysfunction induced by 6-OHDA in striatal slices.

Authors:  C M Massari; L C Constantino; C I Tasca
Journal:  Purinergic Signal       Date:  2021-02-06       Impact factor: 3.765

4.  Guanosine Mechanisms of Action: Toward Molecular Targets.

Authors:  Caio M Massari; Mariachiara Zuccarini; Patrizia Di Iorio; Carla I Tasca
Journal:  Front Pharmacol       Date:  2021-03-31       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.